
















There is longstanding recognition of the striking 
association between ageing in humans and the incidence 
rates of many common types of cancer.  The biological 
basis of this link is likely to be multi-factorial including 
both age-associated decline in anti-oncogenic functions, 
such as repair of oxidative damage to DNA, timing of 
etiologic exposures and/or protracted time required for 
accumulation of a full set of oncogenic mutations [1, 2]. 
 
Acute leukemias have an unusual age-associated 
incidence with a peak at a young age (2-5 years) 
followed by a later increasing incidence with age in 
adults.  In this instance, however, the biological and 
genetic subtypes of leukemia are distinct at different 
ages [3]. 
 
BCR-ABL1 gene fusion is the result of the 
‘Philadelphia’ chromosome – the first specific genetic 
abnormality described in cancer and which is a 
translocation between chromosomes 9 and 22 [4].  Two 
versions of the fusion exist involving different exons of 
BCR and generating two different sized proteins: p210 
BCR-ABL1 predominantly associated with chronic 
myeloid leukemia and p190 BCR-ABL1 linked to B cell 
precursor acute lymphoblastic leukemia (ALL).  Both 
sub-types of leukemia have increased incidence with age. 
 
So what might be the biological basis of the age-
associated incidence of B-ALL with p190 BCR-ABL1?  
Vicente-Dueñas et al [5] designed a novel experiment to 
address this question which conveniently bypassed 
uncertainties over required exposures for the natural 
disease and age-associated alterations in the host tissue 
micro-environment.  Using an inducible p190 BCR-
ABL transgene, they found that ‘old’ (= 20 months) 
cells develop leukemias at a much faster rate (~2x) than 



















pients of the same age (4 weeks).  The key to the 
experiment is that BCR-ABL1 expression is not 
activated until after the transplant. 
 
Although all mice eventually developed ALL, this result 
is compatible with the notion that ‘old’ B progenitors 
have some competitive advantage when expressing 
BCR-ABL1.  What might this be?  A plausible 
explanation is offered in another paper recently 
published by Henry et al [6].  This group have 
previously suggested that age-related fitness decline in 
stem and progenitor cells might increase selective 
pressure for oncogenic mutations [7].  In their new 
study [6], they also evaluated the impact of age on the 
transformability of hematopoietic cells by p190 BCR-
ABL1.  In their case, this was performed by transfecting 
‘young’ (2 months) versus ‘old’ (22-24 months) bone 
marrow cells with a p190 BCR-ABL retrovirus and 
transplanting these into recipients which were selected 
to provide either ‘young’ (2 months) or ‘old’ (22-24 
months) competitor normal cells.  They observed higher 
rates of leukemia (up to 200 days post-transplant) with 
transfer of ‘older’ cells.  More rapid onset of leukemia 
in aged p190 BCR-ABL1 cells or more efficient 
leukemogenesis probably reflects more ‘target’ cells 
being transformed which, in turn, would increase the 
probability of the acquisition of secondary genetic 
abnormalities such as IKZF1 deletion which, at least for 
leukemia in patients with BCR-ABL1+ ALL, appear to 
be critical for malignant progression [8].  This 
interpretation accords with the observation of Henry et 
al [6] that ‘older’ mouse cells transfected with BCR-
ABL1 undergo more rapid polyclonal expansion early 
after transplantation. 
 
Additionally, Henry et al [6] observed that ‘young’ 
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cells, indicating that the age-associated leukemogenesis 
involves both cell intrinsic (or autonomous) and 
extrinsic factors perhaps related to competitive 
occupancy of critical bone marrow niches.  Henry et al 
argue that BCR-ABL1 actually has more potent selective 
advantage in older cells because it restores defective 
kinase signalling in ageing cells.  They provide 
supportive evidence for this by showing increased 
expansion of young BCR-ABL1+ B cell progenitors 
under conditions of reduced kinase signalling via the 
regulatory molecule IL7 [6]. 
 
These data are compelling but one alternative 
explanation might also be considered.  B cell 
lymphopoiesis declines dramatically with age in both 
mice and humans and this inevitably produces 
substantial changes in the cellular architecture of bone 
marrow [9].  Transforming functions of oncogenes, 
including leukemic fusion genes, in very cell context 
dependent [10].  It is possible that it is not only some 
qualitative feature of the target cell that changes with 
age but the number of the appropriate cells available for 
transformation. 
 
With ionizing radiation-induced ALL, children [11] or 
young mice [12] are more vulnerable, as are young 
post-adolescent females with respect to irradiation-
induced breast cancer [13].  This is most easily 
interpreted as reflecting age-associated changes in the 
number and proliferative activity of the particular stem 
and progenitor cells that provide the vulnerable ‘targets’ 
for transformation. 
 
Whatever the mechanisms, or combination of 
mechanisms, involved, these two new papers add a new 
dimension to our understanding of the complexity of 
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